Table 1. Baseline clinical and demographic patient characteristics.
| All | No P2Y12 inhibitor | p Value | P2Y12 inhibitor | p Value | p Value no P2Y12 vs. P2Y12 inhibitors | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low PFS | Medium PFS | High PFS | Low PFS | Medium PFS | High PFS | |||||
| N | 220 | 9 | 43 | 63 | 31 | 36 | 13 | |||
| Age (mean ± SD) | 64.9 ± 11.0 | 58.7 ± 9.3 | 67.9 ± 10.2 | 65.2 ± 11.5 | 0.066 | 64.9 ± 9.4 | 62.2 ± 11.7 | 69.4 ± 9.3 | 0.106 | 0.150 |
| Sex (n, % males) | 153 (69.5) | 6 (66.7) | 24 (55.8) | 44 (69.8) | 0.330 | 24 (77.4) | 28 (77.8) | 7 (53.8) | 0.204 | 0.101 |
| Diabetes (n, %) | 51 (23.3) | 1 (11.1) | 11 (25.6) | 16 (25.4) | 0.628 | 6 (20.0) | 10 (27.8) | 3 (23.1) | 0.760 | 0.920 |
| Hypertension (n, %) | 127 (57.7) | 7 (77.8) | 28 (65.1) | 35 (55.6) | 0.341 | 13 (41.9) | 21 (58.3) | 8 (61.5) | 0.316 | 0.470 |
| Hypercholesterolemia (n, %) | 106 (50.0) | 4 (50.0) | 22 (52.4) | 32 (50.8) | 0.984 | 14 (45.2) | 14 (43.8) | 4 (36.4) | 0.877 | 0.675 |
| Smoking (n, %) | 106 (54.6) | 4 (50.0) | 21 (61.8) | 26 (48.1) | 0.452 | 16 (57.1) | 18 (51.4) | 8 (66.7) | 0.649 | 0.569 |
| Kidney failure (n, %) | 7 (3.2) | 0 (0.0) | 2 (4.7) | 2 (3.2) | 0.772 | 1 (3.2) | 1 (2.8) | 0 (0.0) | 0.814 | 1.000 |
| BMI (mean ± SD) | 27.1 ± 4.2 | 27.1 ± 3.3 | 28.5 ± 4.9 | 25.9 ± 4.1 | 0.016 | 26.8 ± 3.6 | 26.7 ± 2.7 | 29.4 ± 5.8 | 0.084 | 0.928 |
| History of ACS (n,%) | 75 (34.1) | 2 (22.2) | 12 (27.9) | 17 (27.0) | 0.941 | 13 (41.9) | 17 (47.2) | 4 (30.8) | 0.587 | 0.040 |
| History of PCI (n,%) | 69 (31.4) | 1 (11.1) | 13 (30.2) | 14 (22.2) | 0.403 | 14 (45.2) | 13 (36.1) | 6 (46.2) | 0.699 | 0.050 |
| History of CABG (n,%) | 35 (15.9) | 2 (22.2) | 5 (11.6) | 12 (19.0) | 0.535 | 5 (16.1) | 3 (8.3) | 2 (15.4) | 0.593 | 0.425 |
Abbreviations: ACS, acute coronary syndrome; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; PFS, platelet function score; SD, standard deviation.
Note: Data are shown as number of participants and percentage or mean with SD. When data were incomplete, the percentage of participants that was accessible was calculated. PFS was assessed by stratifying the platelet reactivity per agonist in tertiles (1, 2, and 3) for fibrinogen binding. Significant values (p < 0.05) are given in bold.